Xonef eye drops 0.5% 5ml

SKU: 219dfab83902 Category:



Xonef eye drops – is an antiglaucoma drug, which is available in the form of eye drops. The active substance belongs to the group of selective beta-blockers, which lead to a reduction in intraocular pressure by decreasing fluid production. Due to possible systemic effects, care should be taken when prescribing this medication to people with concomitant diseases of the respiratory and cardiovascular systems.

Xonef eye drops – antiglaucoma preparation.

Selective beta-1-adrenoblocker without internal sympathomimetic activity. Does not have a membrane-stabilizing (local anesthetic) action.

With topical application, betaxolol reduces intraocular pressure by reducing the production of intraocular fluid.

The onset of hypotensive action is observed 30 minutes after instillation, the maximum effect develops after 2 hours. After a single instillation, the effect on the ophthalmotonus persists for 12 hours.

Betaxolol (in comparison with other beta-adrenoblockers) does not cause a decrease in blood flow in the optic nerve.

The use of eye drops Xonef does not lead to the formation of miosis, spasm of accommodation, hemeralopia (in contrast to myotics).


As a monotherapy:

  • to reduce intraocular pressure.

In combination with other drugs with:

  • open-angle glaucoma;
  • ocular hypertension.


  • sinus bradycardia;
  • AV blockade II and III degree;
  • severe heart failure;
  • cardiogenic shock;
  • arterial hypotension;
  • children’s age till 18 years;
  • hypersensitivity to the components of the drug.

With caution should apply the drug with thyrotoxicosis, myasthenia gravis, diabetes mellitus, Raynaud’s syndrome, pheochromocytoma, bronchial asthma, chronic obstructive bronchitis.

Special instructions:

Caution is prescribed to patients with diabetes mellitus, since beta-blockers may mask the symptoms of acute hypoglycemia.

With caution appoint the drug to patients with thyrotoxicosis, tk. beta-blockers may mask the symptoms of thyrotoxicosis (eg, tachycardia). Patients with suspected thyrotoxicosis should not abstain from beta-blockers, this can cause an increase in symptoms.

It should be borne in mind that beta-blockers can cause symptoms similar to those in myasthenia gravis (diplopia, ptosis, general weakness).

Caution should be given to beta-blockers in patients with severe impairment of the function of the respiratory system. Despite the fact that in clinical studies the absence of betaxolol in the ophthalmic dosage form on the function of external respiration has been shown, it is impossible to exclude the possibility of hypersensitivity to the drug.

Before the planned surgery, you should gradually cancel the beta-blockers 48 hours before the general anesthesia, tk. during general anesthesia, they can reduce the sensitivity of the myocardium to sympathetic stimulation.

Patients who use beta-blockers may have a history of atopy or anaphylactic reactions. In the case of the development of repeated reactions of hypersensitivity, such patients may not be sensitive to the usual doses of epinephrine (adrenaline) necessary for arresting anaphylaxis.

The drug should be administered with caution to patients with Reynaud’s syndrome or pheochromocytoma.

When instilled in the eye, beta-blockers can be absorbed into the systemic circulation. In this case, the same side effects can be noted, as in systemic application. Cases of severe respiratory and cardiovascular disorders, including bronchospasm with fatal outcome in patients with bronchial asthma and death from heart failure are described.

Xonef has minimal impact on blood pressure and heart rate. However, care should be taken when administering the drug to patients with grade I AV blockade and mild to moderate heart failure. Treatment with Xonefs should immediately stop when the first symptoms of cardiovascular decompensation appear.

Xoneph has a preservative of benzalkonium chloride, which can be deposited on soft contact lenses and have a toxic effect on the eye tissue. Therefore, patients wearing contact lenses should be removed before using drops and installed back no earlier than 20 minutes after instillation.

Impact on the ability to drive vehicles and manage mechanisms

If, after the application of droplets, patients temporarily lose visual clarity, it is not recommended to drive vehicles and engage in activities requiring increased attention and reaction before recovery.

Suggested Use:

The drug is instilled in the conjunctival sac 1-2 drops 2 times / day.

In some patients, intraocular pressure stabilization occurs within a few weeks, therefore it is recommended to monitor intraocular pressure during the first month of treatment.

With insufficient clinical efficacy of monotherapy, additional therapy is prescribed.


  • Comes in original packaging. Item is brand new and unopened.


  • Keep away from direct sunlight.
  • Keep locked and away from children.
  • Store in dry place at room temperature.
  • Do not exceed storage temperature higher than 25 C

Important notice– the outer box design may vary before prior notice!